The primary aims of this application will be to develop synthetic agents that can recognize the exterior surface of proteins and disrupt clinically important protein-protein interactions. We will exploit the unique distribution of charged, hydrophobic and hydrophilic groups on the surface of every protein to identify artificial receptors that bind selectively and potentially disrupt biological function. A central feature of our approach will be the design of synthetic agents that contain a large (>400 Angstrom 2) and functionalized surface area to recognize the complementary surface of the target protein. In the previous project period we have shown that this strategy can lead to protein binding agents that show high affinity (nM-pM) for specific protein targets, are selective among a range of different proteins, are effective in conditions of high salt concentration and can disrupt protein-protein interactions in vivo. Within these primary goals we will have the following specific aims:
Specific Aim 1 - To develop synthetic receptors that bind with high affinity and selectivity to growth factor proteins (including PDGF, VEGF, EGF and FGF) involved in aberrant cell proliferation pathways.
Specific Aim 2 - To develop synthetic agents that bind to the surface of cytochrome c and disrupt its interaction with Apaf-1 to form the apoptosome. We will target the exterior surface of cytochrome c that is involved in its interactions with protein partners.
Specific Aim 3 - To develop synthetic ligands that bind selectively to the surface of phosphorylated proteins and signal their presence through fluorescence emission changes. We will develop binding agents that target the phosphotyrosine groups on the surface of activated signaling proteins, such as Bcr-Abl, STAT3 and Src using a cyclic tris-biphenylamide scaffold.
Specific Aim 4 - To develop arrays of fluorescent binding agents that can be used to detect proteins with different surface properties and to optimize binding selectivities for other targets. We will develop solution and solid phase arrays of fluorescent protein binding agents that show distinctive patterns of quenching in the presence of proteins with different surface recognition characteristics.
| Tsou, Lun K; Chen, Chin-Ho; Dutschman, Ginger E et al. (2012) Blocking HIV-1 entry by a gp120 surface binding inhibitor. Bioorg Med Chem Lett 22:3358-61 |
| Tsou, Lun K; Dutschman, Ginger E; Gullen, Elizabeth A et al. (2010) Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold. Bioorg Med Chem Lett 20:2137-9 |
| Ross, Nathan T; Katt, William P; Hamilton, Andrew D (2010) Synthetic mimetics of protein secondary structure domains. Philos Trans A Math Phys Eng Sci 368:989-1008 |
| Jain, Rishi K; Tsou, Lun K; Hamilton, Andrew D (2009) Combined solid/solution phase synthesis of large surface area scaffolds derived from aminomethyl-benzoates. Tetrahedron Lett 50:2787-2789 |
| Margulies, David; Hamilton, Andrew D (2009) Digital analysis of protein properties by an ensemble of DNA quadruplexes. J Am Chem Soc 131:9142-3 |
| Margulies, David; Opatowsky, Yarden; Fletcher, Steven et al. (2009) Surface binding inhibitors of the SCF-KIT protein-protein interaction. Chembiochem 10:1955-8 |
| Wyrembak, Pauline N; Hamilton, Andrew D (2009) Alkyne-linked 2,2-disubstituted-indolin-3-one oligomers as extended beta-strand mimetics. J Am Chem Soc 131:4566-7 |
| Margulies, David; Hamilton, Andrew D (2009) Protein recognition by an ensemble of fluorescent DNA G-quadruplexes. Angew Chem Int Ed Engl 48:1771-4 |
| Gustafsdottir, Sigrun M; Wennstrom, Stefan; Fredriksson, Simon et al. (2008) Use of proximity ligation to screen for inhibitors of interactions between vascular endothelial growth factor A and its receptors. Clin Chem 54:1218-25 |
| Wilson, Andrew J; Hong, Jason; Fletcher, Steven et al. (2007) Recognition of solvent exposed protein surfaces using anthracene derived receptors. Org Biomol Chem 5:276-85 |
Showing the most recent 10 out of 42 publications
